What is the complication rate for cosmetic limb lengthening?

Peer-reviewed literature reports a 30-45% any-complication rate and 5-15% serious-complication rate (non-union, nerve injury, deep infection) for cosmetic limb lengthening. High-volume surgeons cluster at the low end (~5% serious). The Stryde nail recall added 5-10% corrosion-related pain in Stryde patients.

Is limb lengthening surgery safe in 2026?

Limb lengthening surgery has a 30-45% any-complication rate and 5-15% serious-complication rate per peer-reviewed literature. Safety is heavily surgeon-dependent — high-volume surgeons (>50 cases/year) report serious complications closer to 5%. The Stryde nail was recalled by the FDA in April 2021 and is no longer implanted.

What is the Stryde recall?

The PRECICE Stryde nail received an FDA Class I recall in April 2021 due to corrosion at the telescoping junction. NuVasive paused distribution. Stryde is no longer offered to new patients in 2026 by ethical clinics. Existing Stryde patients should have it monitored or removed at 12-18 months post-op.

What is the most common serious complication of limb lengthening?

Delayed union or non-union is the most common serious complication, affecting 2-8% of cosmetic LL cases per JOSR 2025 systematic review. Internal-nail methods cluster at the low end (2-4%); external-fixator and hybrid methods cluster higher (6-8%). Risk factors include smoking, distraction faster than 1 mm/day, weight-bearing too soon, low vitamin D, and patient age above 45.

Why does surgeon volume matter more than method?

High-volume surgeons (>50 cosmetic LL cases per year) report serious-complication rates clustering at ~5%. Low-volume surgeons (<10 cases per year) can exceed 15%. The 3× gap between high and low volume is larger than the gap between any two methods, making surgeon experience the single most important predictor of outcome.

01Complications

Limb lengthening complications: what 1,847 cases tell us.

Every honest conversation about limb lengthening surgery begins with the complication rate. The 2025 JOSR systematic review (PMC11415641) pooled 1,847 cosmetic cases across 22 published series and found a 32.4% any-complication rate. We mapped those numbers against our 44-clinic directory to show you where the risk actually lives — and where it does not.

02By the numbers

30–45% any-complication. 5–15% serious. The spread is the story.

The peer-reviewed range across cosmetic-indication series sits between 30% and 45% for any documented event. Serious complications — non-union, nerve injury, deep infection, refracture — concentrate between 5% and 15% depending on method and surgeon volume. The variance within a single method is larger than the gap between methods, which is the single most important fact on this page.

32.4%

Any complication (pooled, JOSR 2025)

5–15%

Serious complication band

1,847

Pooled cosmetic cases reviewed

Series included in systematic review

One headline misses the spread. Internal-nail series report any-complication rates of 15–25% with serious complications between 2% and 5%. Hybrid LON series report 25–40% any-complication and 5–10% serious. Pure external-fixator (Ilizarov) series still trend 30–50% any-complication and 8–15% serious — the highest in cosmetic indication. The full source is in our research index.

03The big four

The four serious complications that matter.

Minor events — pin-site irritation, transient stiffness, mild swelling — resolve on their own and dominate the headline rate. The four below are the ones that change outcomes, require revision surgery, or never fully resolve. Every clinic in our directory has been asked which of these they publish data for.

Non-union · 2–8% of cases

Non-union — the new bone never hardens.

Non-union and delayed union describe a regenerate that fails to consolidate on schedule. JOSR 2025 reports 5.1% delayed union pooled across methods. Internal-nail series (PRECICE) cluster at the low end (2–4%). External-fixator and hybrid series (LON, Ilizarov) cluster at 6–8%. Risk factors: smoking, distraction rate faster than 1 mm/day, weight-bearing too soon, low vitamin D, and patient age above 45.

Treatment is typically a revision surgery — bone grafting, dynamization of the nail, or external-fixator augmentation. Adds 3–6 months to the timeline.

Nerve injury · 1–6% of cases

Nerve injury — peroneal palsy, sensory loss, foot drop.

Distraction stretches the peripheral nerves alongside the bone. Most stretch is tolerated; some is not. JOSR 2025 reports 3.2% nerve compression pooled. Tibial lengthening carries the higher risk (peroneal nerve), femoral the lower. Most cases (~80%) are transient — paraesthesia and weakness that resolve over 3–9 months. The remaining 20% are permanent: persistent foot drop, sensory loss, or chronic neuropathic pain.

Risk control: slower distraction rate (0.75 mm/day instead of 1.0), nightly EMG in high-risk patients, prophylactic peroneal nerve decompression in tibial cases. Surgeon experience matters more than method here.

Deep infection · 1–4% of cases

Deep infection — the implant has to come out.

Superficial pin-site infections affect 20–40% of external-fixator patients during distraction and clear with oral antibiotics. Deep infection — osteomyelitis or implant-tract sepsis — is the dangerous category. Internal-nail series (PRECICE) report 1–2%. Hybrid LON and Ilizarov series report 3–4%, because the pin-bone interface creates a permanent contamination route during the entire fixator period.

Treatment requires implant removal, surgical debridement, 6–12 weeks of IV antibiotics, then reimplantation if the patient still wants to complete lengthening. Total timeline impact: 6–12 months.

Refracture · 1–3% of cases

Refracture — usually the patient's fault.

The new bone is fragile through the consolidation phase. Patients who return to impact sport at 6–9 months instead of 12+ months account for the disproportionate share of refractures in case-series follow-up data. Internal-nail patients have a false sense of recovery: no visible hardware means no visible warning. The bone is still half-formed.

Treatment: re-immobilisation, repeat consolidation, sometimes a second internal nail. Avoidable in 90% of cases by following the surgeon's return-to-sport protocol. The single biggest patient-side risk factor in the literature.

04By method

PRECICE 2 vs LON vs Ilizarov — complication-rate side by side.

Same indication (cosmetic lengthening). Same expected gain (5–8 cm per segment). Three different complication profiles. The method ranges below come from our method spec library, cross-checked against systematic-review pooled rates.

Method	Hardware	Complication rate	Clinics offering
PRECICE 2 Internal nail	inside bone	15–25% all complications; 2–5% serious	35verified
LON (Lengthening Over Nail) Hybrid	inside + outside	25–40% all complications; 5–10% serious	27verified
Ilizarov External fixator	outside the skin	30–50% all complications; 8–15% serious	31verified

For cosmetic indication, internal-nail systems carry the lowest published complication profile and have become the standard of care at most Tier 1 centers since 2019. LON is the cost-effective hybrid — dominant in Turkey, with a defensible safety record at high-volume clinics. Ilizarov is now reserved mostly for reconstructive cases (length discrepancy, dwarfism), not cosmetic. Read the side-by-side spec at /methods/precice-vs-lon.

05The Stryde recall

The Stryde recall — and why it still matters in 2026.

The PRECICE Stryde nail received an FDA Class I recall — the most serious tier — in April 2021 following multiple reports of corrosion at the telescoping junction and associated bone changes. NuVasive paused US distribution. The recall remains active. A small number of clinics outside the US continued offering Stryde into 2022–2023; in 2026 it is no longer implanted at any clinic in our directory.

Existing Stryde patients should follow their surgeon's monitoring protocol — typically radiographic imaging every 6–12 months — and discuss elective implant removal once consolidation is complete (12–18 months post-implant). 5–10% of Stryde patients have reported pain or radiographic changes warranting removal earlier. If a clinic still advertises Stryde on its method menu, ask explicitly whether the clinic implants it today and how it monitors existing patients.

Full FDA Class I notice and our methods spec at /methods/stryde-vs-precice.

06Surgeon volume

Surgeon volume matters more than method.

The most overlooked statistic in the literature: high-volume surgeons (more than 50 cosmetic lengthening cases per year) report serious-complication rates clustering at ~5%. Low-volume surgeons (fewer than 10 cases per year) report rates that can exceed 15%. The 3× gap is larger than the gap between any two methods. It is the single most actionable number on this page.

High-volume surgeon

~5%

Serious complication rate at >50 cosmetic LL cases per year. Examples in our directory: Paley (FL), Mahboubian (NV), Rozbruch (NYC), Buldu (Istanbul), Yurttas (Istanbul).

Low-volume surgeon

15%+

Serious complication rate at <10 cases per year. Common at general orthopedic practices that take occasional cosmetic LL referrals. The cheapest quotes disproportionately come from this category.

Of our 44 verified clinics, the 9 surgeons we profile on /surgeons are all in the high-volume category — that is part of how we Tier the directory.

07Late complications

Five-year and ten-year outlook.

Long-term follow-up is the weakest part of the cosmetic-LL evidence base. Most published series report 12–24 month outcomes. What we know about 5–10 year follow-up comes from the reconstructive (limb-length-discrepancy, dwarfism) literature, which shares anatomy but not the same patient mix.

Year 2–5

Most internal nails have been removed (12–18 months). Bone density at the regenerate continues to remodel and approaches native bone by month 24–36. Minor gait asymmetry in some patients resolves with continued physiotherapy. Persistent joint pain — knee or ankle — is reported in 5–8% of long-term follow-up.

Year 5–10

Late refractures are vanishingly rare past year 5. Hip and ankle osteoarthritis in middle age occurs at slightly higher rates than the general population in two-stage patients (femur + tibia), per reconstructive-cohort data. Patients who lengthened beyond 8 cm per segment carry the higher osteoarthritis signal.

Beyond year 10

Evidence thins to case reports. Cosmetic-indication 10-year follow-up papers are rare. The anatomical principle is that the new bone is permanent and behaves like native bone after consolidation; problems past year 10 are almost always joint-mediated rather than bone-mediated.

08Read the rate

How to read a clinic's complication rate.

Most clinics either do not publish their complication rate or publish a number that is unverifiable. The questions below filter the difference between a clinic that owns its data and a clinic that hopes you do not ask.

1. How many cosmetic-indication LL cases did the lead surgeon perform last calendar year?
Anything under 30 cases per year is low-volume. Anything above 75 is high-volume.
2. What is the published any-complication rate? What is the serious-complication rate?
A clinic that cannot separate the two has not measured them.
3. How many revision surgeries did the lead surgeon perform on their own cases last year?
Hidden revision counts are the easiest way to suppress a complication rate.
4. What is the published rate of permanent (not transient) nerve injury?
The transient/permanent distinction is the line between "we follow up" and "we hope".
5. Will you share an anonymised list of complications from the last 24 months?
A clinic that says yes is in a different category from one that says no.

Free editor review · No obligation

Get matched with a clinic that publishes its complication data.

We narrow the 44-clinic directory to 2–3 matches based on the data they actually publish, your country, and your method preference. First clinic consult is usually free.

Request an introduction →